The authors demonstrated that tumor-cell HLA-DR expression correlates with immune checkpoint activation, PD-L1 co-expression, CD8+ T-cell recruitment and exhaustion, and unfavorable clinical outcomes. The gene discussed is CD274; the disease is neoplasm.